Congenital Adrenal Hyperplasia Market Research Report- Forecast Till 2030

Congenital Adrenal Hyperplasia Market Research Report- Type (Classic CAH, And Non-Classic CAH), Treatment & Diagnosis (Diagnosis (Gene Testing, Amniocentesis), Treatment (Medication, Surgery)), End User (Hospital, Clinics) - Forecast till 2030

ID: MRFR/Pharma/3515-HCR | | Region: Global | 85 Pages         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Congenital Adrenal Hyperplasia Market, by Type

6.1 Introduction

6.2 Classic CAH, and

Market Estimates & Forecast, 2020 – 2027

6.3 Non-Classic CAH

Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Congenital Adrenal Hyperplasia Market, by Diagnosis & Treatment

7.1 Introduction

7.2 Diagnosis

Market Estimates & Forecast, 2020 – 2027

7.2.1 Amniocentesis

7.2.2 Chorionic Villus Sampling

7.2.3 Blood and Urine Tests

7.2.4 Gene Testing

7.2.5 Physical Exam

7.2.6 Others

7.3 Treatment

Market Estimates & Forecast, 2020 – 2027

7.3.1 Medications

7.3.1.1 Glucocorticoids

7.3.1.2 Mineralocorticoids

7.3.1.3 Salt Supplements

7.3.1.4 Others

7.3.2 Surgery

Chapter 8. Global Congenital Adrenal Hyperplasia Market, by End User

8.1 Introduction

8.2 Hospitals

Market Estimates & Forecast, 2020 – 2027

8.3 Clinics

Market Estimates & Forecast, 2020 – 2027

8.4 Others

Chapter 9. Global Congenital Adrenal Hyperplasia Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Neurocrine Biosciences, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Sanofi

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 GlaxoSmithKline Plc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Fusion IP plc

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Mitsubishi Chemical Holdings Corporation

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Novartis AG

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 F. Hoffmann-La Roche Ltd

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

Chapter 13 Appendix

DATA TABLES

Table 1 Congenital Adrenal Hyperplasia Industry Synopsis, 2020 – 2027

Table 2 Global Congenital Adrenal Hyperplasia Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Congenital Adrenal Hyperplasia Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Congenital Adrenal Hyperplasia Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 6 Global Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Congenital Adrenal Hyperplasia Market by Types, 2020 – 2027, (USD Million)

Table 8 North America Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 9 North America Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 10 US Market by Types, 2020 – 2027, (USD Million)

Table 11 US Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 12 US Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Market by Types, 2020 – 2027, (USD Million)

Table 14 Canada Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 15 Canada Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Market by Types, 2020 – 2027, (USD Million)

Table 17 South America Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 18 South America Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 19 Europe Market by Types, 2020 – 2027, (USD Million)

Table 20 Europe Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 21 Europe Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Market by Types, 2020 – 2027, (USD Million)

Table 23 Western Europe Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 24 Western Europe Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Congenital Adrenal Hyperplasia Market by Diagnosis & Treatment, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Congenital Adrenal Hyperplasia Market by End Users, 2020 – 2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Congenital Adrenal Hyperplasia Market

Figure 3 Segmentation Market Dynamics for Global Congenital Adrenal Hyperplasia Market

Figure 4 Global Congenital Adrenal Hyperplasia market Share, by type 2020

Figure 5 Global Congenital Adrenal Hyperplasia market Share, by Diagnosis & Treatment 2020

Figure 6 Global Congenital Adrenal Hyperplasia Market Share, by End Users, 2020

Figure 7 Global Congenital Adrenal Hyperplasia Market Share, by Region, 2020

Figure 8 North America Congenital Adrenal Hyperplasia Market Share, by Country, 2020

Figure 9 Europe Congenital Adrenal Hyperplasia Market Share, by Country, 2020

Figure 10 Asia Pacific Congenital Adrenal Hyperplasia Market Share, by Country, 2020

Figure 11 Middle East & Africa Congenital Adrenal Hyperplasia Market Share, by Country, 2020

Figure 12 Global Congenital Adrenal Hyperplasia Market: Company Share Analysis, 2020 (%)

Figure 13 Neurocrine Biosciences, Inc.: Key Financials

Figure 14 Neurocrine Biosciences, Inc.: Segmental Revenue

Figure 15 Neurocrine Biosciences, Inc.: Geographical Revenue

Figure 16 Sanofi: Key Financials

Figure 17 Sanofi: Segmental Revenue

Figure 18 Sanofi: Geographical Revenue

Figure 19 GlaxoSmithKline Plc: Key Financials

Figure 20 GlaxoSmithKline Plc: Segmental Revenue

Figure 21 GlaxoSmithKline Plc: Geographical Revenue

Figure 22 Fusion IP plc: Key Financials

Figure 23 Fusion IP plc: Segmental Revenue

Figure 24 Fusion IP plc: Geographical Revenue

Figure 25 Mitsubishi Chemical Holdings Corporation: Key Financials

Figure 26 Mitsubishi Chemical Holdings Corporation: Segmental Revenue

Figure 27 Mitsubishi Chemical Holdings Corporation: Geographical Revenue

Figure 28 Novartis AG: Key Financials

Figure 29 Novartis AG: Segmental Revenue

Figure 30 Novartis AG: Geographical Revenue

Figure 31 F. Hoffmann-La Roche Ltd: Key Financials

Figure 32 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 33 F. Hoffmann-La Roche Ltd: Geographical Revenue

Congenital Adrenal Hyperplasia Market Speak to Analyst Request a Free Sample

Congenital Adrenal Hyperplasia Market Overview:


The congenital adrenal hyperplasia industry projects at a CAGR of 7.80% during the market forecast period of 2020-2030. This disorder is a genetic disorder that affects especially the adrenal glands. This disorder is caused due to the lack of CAH enzymes. This enzyme is used for producing hormones that control the metabolism, the immunity system along with blood pressure, and some of the physiological functions. These disorders are very much common both in children and in infants. From congenital adrenal hyperplasia market research, you will note that this disorder involves several diagnostic tests that diagnose these disorders well. As per the National Institute of Child Health and Human Development, it was marked that about 18000 children suffer from this disorder every year. The market analysis covers the uptake by drugs, sales of every drug and the therapies so conducted.


From the congenital adrenal hyperplasia market analysis, it is found that the congenital adrenal hyperplasia industry is a fragmented one. It summarizes the key players that they highly focus on building partnerships, collaborating, and then merging with them. Globally it has been noted that technology has helped the industry to launch new and innovative products for which the key players occupy a large congenital adrenal hyperplasia market share. The report gives insights into the integrated solutions for which the business can grow, mature, and evolve safely.


The report highlights the data collection methods along with an increased inability to track market expansion products. The report offers comprehensive information about the integrated solutions and gives a good combination of the research methodologies. The congenital adrenal hyperplasia market report gives a thorough understanding of the definition, segmentation, classification, and also about symptoms. The report also summarizes the treatment algorithms and treatment guidelines for CAH in some of the regions.


COVID 19 ANALYSIS


The outbreak of the pandemic leads to the spreading up of diseases throughout the world. Most of the population suffered the loss of either family members or faced a shortage of money. Most manufacturing units manufacturing certain devices faced shutdown. Lockdown was experienced throughout the nation. As per the government's rules and regulations, the lockdown and the shutdown so faced had a bad effect on healthcare units and the market.


Market Dynamics



  • Drivers- The congenital adrenal hyperplasia market is driven by the growing prevalence of this disorder in the market, unmet needs which are required for treating genetic related disorders drive up the diastematomyelia market size. Growth in demand for acquiring better and effective medicines and drugs for the treatment of congenital adrenal disorders. During the last few years, the number of people suffering from this disorder has risen. The government has supported the research institutes and the manufacturers who involve themselves in research and developmental activities and introduce good treatments for genetic disorders.

  • Opportunities- Arise in government support and the development facilities provided by the government steers up the diastematomyelia market size. The actual treatment for this disorder is not at all available in the market. Market growth takes place due to the classic rise in hyperplasia and the demand for its drugs among the population. The good infrastructure of the healthcare and medicals in fact drives up the market growth.

  • Challenges- Most of the emerging regions are said to be the safest place for drugs and surgeries, this becoming a challenging factor for the congenital adrenal hyperplasia market. Funding facilities and the rise in key players in the market becomes a challenging factor for growth and size expansion.

  • Cumulative Growth- The rise in market value at a high CAGR rate expanded the market growth and the market size during the market forecast period.

  • Restraints- Rise in costs of treatment of the disorder and the lessening up of availability of the precise treatment degrades the market growth and degrades the market size. So high costs act as a restraining factor in developing countries and emerging countries. The financial lucidity of the users has made them much more independent to spend much more money on their health issues.


Market Segmentation



  • By type- The market is classified based on type, diagnosis, treatment, and end-users. Based on type, the market is divided into classic CAH and non-classic CAH. Based on diagnosis and treatment, the market is divided into diagnosis and treatment. The diagnosis part is further subdivided into amniocentesis, chorionic villus sampling, test for blood and urine, testing of the gene, physical exam, and many more. Treatment is again subdivided into medications and surgery. Medications are again divided into glucocorticoids, mineralocorticoids, supplements of salt, and many more. Based on end-users, the market is classified into hospitals, clinics, medicals, and many more.

  • By technology- Technology has led to the advancement in gaining newborn screening, measuring the steroid content by using mass spectrometry, manufacturing glucocorticoid so required where people can take stress, treating the side effects caused by various drugs, helps in the prenatal treatment, treatment of fertility and morbidity rate and helps in identifying the gender. Technology leads to the discovery of morphological features in the patients. Technology-led to a longitudinal study of the facial morphology where the bio makes can understand the lifespan outcome of the patients.


Regional Analysis


The United States occupies the most dominant position in the congenital market. This is due to the rise in the number of patients suffering from congenital adrenal hyperplasia disorder. Due to an increase in the population, the government has suffered from inventing new and innovative drugs as per the new technology. Use of advanced technology, high expenditure on health issues, and the growth in forthright support from the government for both congenital adrenal hyperplasia market research and development. This has increased the growth in this region. The European region is marked to be the second-largest market covering a large area of congenital market share.


Availability of excess funds along with strong investment from the government has helped in driving up the market growth. Germany, the United Kingdom, and France cover a major area and hold a major congenital adrenal market share. The Asia Pacific region is said to be the fastest-growing region. This is due to the rise in the number of patients suffering from genetic disorders. This region gives a huge opportunity which helps in raising the market growth and its development. Growth in both congenital adrenal hyperplasia market revenue and diastematomyelia market revenue fuels up the market demand during the market forecast period. The Middle East and African region hold the least number of congenital adrenal hyperplasia market shares as here you can find less support from the government. Here the availability of resources as well as medical facilities is found. Owing to the growth in technology some of the Middle East regions cover a major market share. Here high expenditure on medical facilities also takes place. In the region of Africa, you will find more opportunities that bring more growth and development in this region.


Competitive Landscape


Some of the market players playing in the congenital adrenal hyperplasia industry are Neurocrine Biosciences inc. Of the United States, Merck, and Co. Inc of the United States, Fusion IP plc of the United Kingdom, AstraZeneca Plc. of The United Kingdom, Novartis AG of Switzerland, Eli Lilly and Company of the United States, Mitsubishi Chemical Holdings Corporation of Japan, F. Hoffmann La Roche Ltd of Switzerland, Johnson and Johnson of the United States, Abbott of the United States, GlaxoSmithKline Plc of the United States, Allergan of Ireland, Cadila Healthcare of India, Sanofi of France and Macleods Pharmaceuticals of India and many more. These key players are investing much more in the congenital adrenal hyperplasia market research and development on congenital drugs and medicines.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   7.80% (2020-2030)
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Diagnosis & Treatment and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Neurocrine Biosciences, Inc. (U.S.), Fusion IP plc (U.K), Novartis AG (Switerzland), Mitsubishi Chemical Holdings Corporation (Japan), Johnson & Johnson (U.S.), GlaxoSmithKline Plc (U.S.), Cadila healthcare (India), Sanofi (France), Macleods Pharmaceuticals (India), GlaxoSmithKline Plc. (U.K), Allergan (Ireland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Merck & Co., Inc. (U.S.)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of the disorder
  • Unmet needs for the treatment of the genetic disorders
  • Rising demand for better and effective medicines for the treatment


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    congenital adrenal hyperplasia market CAGR would be 7.1% during the forecast period.

    congenital adrenal hyperplasia market report includes end users like hospital, clinic, and others.

    The Asia Pacific congenital adrenal hyperplasia market would grow with the fastest speed.

    The types included in the congenital adrenal hyperplasia market report are classic CAH, and non-classic CAH.

    The Americas would dominate the congenital adrenal hyperplasia market.